Supplementary Figure S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

Bulen, Benjamin J; Khazanov, Nickolay A; Hovelson, Daniel H.; Lamb, Laura E; Matrana, Marc; Burkard, Mark E; Yang, Eddy Shih-Hsin; Edenfield, William J.; Claire Dees, Elizabeth; Onitilo, Adedayo A.; Buchschacher, Gary L; Miller, Alan M; Parsons, Benjamin M.; Wassenaar, Timothy R.; Suga, Jennifer M.; Siegel, Robert D; Irvin, William; Nair, Suresh; Slim, Jennifer N.; Misleh, Jamal; Khatri, Jamil; Masters, Gregory A; Thomas, Sachdev; Safa, Malek M.; Anderson, Daniel M.; Mowers, Jonathan; Dusenbery, Anna C; Drewery, Stephanie; Plouffe, Komal; Reeder, Travis; Vakil, Hana; Patrias, Lynnae; Falzetta, Amanda; Hamilton, Ryan; Kwiatkowski, Kat; Johnson, D. Bryan; Rhodes, Daniel R; Tomlins, Scott A.

doi:10.1158/2767-9764.23618614.v1

crc-23-0036-s01.pdf (727.7 kB)

Supplementary Figure S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

journal contribution

posted on 2023-07-03, 14:20 authored by Benjamin J Bulen, Nickolay A Khazanov, Daniel H. Hovelson, Laura E Lamb, Marc Matrana, Mark E Burkard, Eddy Shih-Hsin Yang, William J. Edenfield, Elizabeth Claire Dees, Adedayo A. Onitilo, Gary L Buchschacher, Alan M Miller, Benjamin M. Parsons, Timothy R. Wassenaar, Jennifer M. Suga, Robert D Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory A Masters, Sachdev Thomas, Malek M. Safa, Daniel M. Anderson, Jonathan Mowers, Anna C Dusenbery, Stephanie Drewery, Komal Plouffe, Travis Reeder, Hana Vakil, Lynnae Patrias, Amanda Falzetta, Ryan Hamilton, Kat Kwiatkowski, D. Bryan Johnson, Daniel R Rhodes, Scott A. Tomlins

Supplementary Figure S1 shows analytical validation of the gene expression component of Immunotherapy Response Score components vs. qRT-PCR

History

ARTICLE ABSTRACT

Immunotherapy Response Score (IRS) integrates tumor mutation burden (TMB) and quantitative expression biomarkers to predict anti-PD-1/PD-L1 (PD-[L]1) monotherapy benefit. Here, we evaluated IRS in additional cohorts. Patients from an observational trial (NCT03061305) treated with anti-PD-(L)1 monotherapy were included and assigned to IRS-High (-H) vs. -Low (-L) groups. Associations with real-world progression free survival (rwPFS) and overall survival (OS) were determined by Cox proportional hazards (CPH) modeling. Those with available PD-L1 immunohistochemistry treated with anti-PD-(L)1 with or without chemotherapy were separately assessed. Patients treated with PD-(L)1 and/or chemotherapy (five relevant tumor types) were assigned to three IRS groups (IRS-L divided into IRS-Ultra-Low [-UL] and Intermediate-Low [-IL] and similarly assessed. In the 352 patient anti-PD-(L)1 monotherapy validation cohort (31 tumor types), IRS-H vs. IRS-L patients had significantly longer rwPFS and OS. IRS significantly improved CPH associations with rwPFS and OS beyond microsatellite instability (MSI)/TMB alone. In a 189 patient (10 tumor types) PD-L1 IHC comparison cohort, IRS, but not PD-L1 IHC nor TMB, was significantly associated with anti-PD-L1 rwPFS. In a 1,103-patient cohort (from five relevant tumor types), rwPFS did not significantly differ in IRS-UL patients treated with chemotherapy vs. chemotherapy plus anti-PD-(L)1, nor in IRS-H patients treated with anti-PD-(L)1 vs. anti-PD-(L)1 + chemotherapy. IRS associations were consistent across subgroups, including both Europeans and non-Europeans. These results confirm the utility of IRS utility for predicting pan-solid tumor PD-(L)1 monotherapy benefit beyond available biomarkers and demonstrate utility for informing on anti-PD-(L)1 and/or chemotherapy treatment.